Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form SC 13G HERON THERAPEUTICS, INC. Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Rezolute, Inc. Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Amalgamated Financial Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Guild Holdings Co Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Werewolf Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Savara Inc Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Verastem, Inc. Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Vinci Partners Investmen Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Aura Biosciences, Inc. Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A VERU INC. Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Nkarta, Inc. Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Praxis Precision Medicin Filed by: Adage Capital Management, L.P.
-
Form SC 13G enGene Holdings Inc. Filed by: Adage Capital Management, L.P.
-
Form SC 13G IMMUNIC, INC. Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A SOLENO THERAPEUTICS INC Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Wave Life Sciences Ltd. Filed by: Adage Capital Management, L.P.
-
Form SC 13G UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
-
Form SC 13G Lexeo Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A Molecular Templates, Filed by: Adage Capital Management, L.P.
-
Form SC 13G Aligos Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SC 13G/A KalVista Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SC 13G TENAX THERAPEUTICS, INC. Filed by: Adage Capital Management, L.P.
-
Form SC 13D GLYCOMIMETICS INC Filed by: Adage Capital Management, L.P.
-
Form SC 13D/A Oruka Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Great Gulf announces minority investment in new ownership group behind purchase of Killington Resort and Pico Mountain
-
SEC Levies More Than $3.8 Million in Penalties in Sweep of Late Beneficial Ownership and Insider Transaction Reports
-
Alphabet, Goldman Sachs and others to settle charges over late filings, SEC says
-
Form N-PX Adage Capital Management For: Jun 30
-
Form N-PX ADAGE CAPITAL PARTNERS For: Jun 30
-
Adage Capital’s $10 Million Gift Launches UNCF’s Project ACCLAIM to Accelerate HBCU Student Pathways into Financial Services
-
Form 13F-NT Adage Capital Management For: Jun 30
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Jun 30
-
Benitec Biopharma (BNTC) Announces Appointment of Kishen Mehta to its Board of Directors
-
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
-
Disc Medicine (IRON) Announces 4.94M Share Offering at $36/sh
-
Disc Medicine Announces Underwritten Offering of Common Stock
-
Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Mar 31
-
Form 13F-NT Adage Capital Management For: Mar 31
-
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
-
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
-
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
-
Form 4 ABEONA THERAPEUTICS INC. For: May 07 Filed by: Adage Capital Management, L.P.
-
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Abeona Therapeutics (ABEO) Prices 12.29M Share and Warrant Offering at $4.07/sh
-
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Form SC 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SC 13G EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form 3 EyePoint Pharmaceuticals For: Apr 18 Filed by: Adage Capital Management, L.P.

